Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Term (2-Year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Galantamine (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- 14 Oct 2021 This trial has been completed in France (End Date: 20 May 2012), according to European Clinical Trials Database record.
- 24 Jun 2013 Results presented at the 11th World Congress of Biological Psychiatry.
- 24 Jun 2013 Primary endpoint 'Mini-Mental-State-Examination' has been met.